Klotho (alpha-Klotho) Therapies
Alpha-klotho is a transmembrane and circulating protein, produced predominantly in kidney and choroid plexus, whose levels decline with age and with chronic kidney disease. It is among the most asked-about longevity targets because of a genuinely striking preclinical record: klotho-deficient mice show accelerated aging phenotypes, klotho-overexpressing mice live longer, a single peripheral dose of alpha-klotho improved cognition in aged rhesus monkeys, and the human KL-VS variant - which raises circulating klotho in heterozygotes - is associated with better cognitive outcomes in several cohorts. What does not exist, as of September 2026, is a controlled human trial showing that raising circulating alpha-klotho improves any clinical outcome. Patients will encounter klotho gene therapy offered through medical-tourism channels, klotho "boosting" supplement stacks, and klotho conference press coverage from small-capitalisation companies. None of these is supported by human efficacy data. This page exists so that conversation can be grounded in what the evidence actually supports.
Evidence Summary
PRECLINICAL (strong). Klotho-deficient mice display a premature-aging syndrome; klotho overexpression extends murine lifespan. Most relevant to current interest, Nature Aging 2023 (Castner, Dudek et al.) reported that a single low peripheral dose of alpha-klotho enhanced cognition in aged rhesus monkeys, with effects persisting well beyond the protein's circulating half-life - the strongest non-human primate result in this area and the basis of most current translational programmes. HUMAN GENETICS AND EPIDEMIOLOGY (moderate, associational). Heterozygosity for the KL-VS variant, which raises circulating klotho, has been associated with better cognitive performance and, in several cohorts, reduced dementia risk, though findings are not uniform across populations and homozygosity has shown opposite or null associations. Circulating klotho concentrations have been associated with biological-age measures and with cardiovascular and renal outcomes in observational cohorts including NHANES-based analyses; all such associations are confounded by kidney function, which is both the dominant source of circulating klotho and an independent determinant of nearly every aging outcome studied. HUMAN INTERVENTIONAL (absent). There is no completed randomised controlled trial demonstrating that increasing circulating alpha-klotho by any route - recombinant protein, gene therapy, encapsulated-cell delivery, or supplement - improves cognition, function, or any hard clinical endpoint. EARLY/COMMERCIAL SIGNAL (September 2026): at the Second Annual Klotho Conference (Miami, 18-19 September 2026), Avai Bio and Austrianova, through their Klothonova joint venture, presented data on producing alpha-klotho from genetically modified encapsulated cells, an approach intended to sustainably restore circulating levels rather than deliver recombinant protein or gene therapy. What is on the record is a conference presentation and associated press releases from a microcap issuer - there is no peer-reviewed publication, no registered efficacy trial, and no human outcome data, and several circulating items are stock-promotion pieces rather than science reporting. Listed here because patients will encounter the coverage, not because it constitutes evidence. Separately, klotho gene therapy is marketed to consumers through offshore clinics; these are unregulated, have published no controlled outcome data, and should not be characterised to patients as treatment.
Evidence Scale
Mechanism of Action
Alpha-klotho exists in a membrane-bound form, acting as an obligate co-receptor for FGF23 in renal phosphate and vitamin D handling, and in a shed/secreted form that circulates and appears to act independently of FGF23. Proposed longevity-relevant mechanisms for the circulating form include suppression of insulin/IGF-1 signalling, inhibition of Wnt and TGF-beta signalling, enhancement of oxidative-stress resistance via FoxO, and effects on synaptic function and NMDA receptor subunit composition that are thought to underlie the cognitive effects seen in rodents and non-human primates. Notably, the cognitive benefit in primates occurred at a peripherally administered dose that is not thought to cross the blood-brain barrier appreciably, implying an indirect, peripherally initiated signalling route that remains incompletely defined. The mechanistic picture is therefore plausible but not settled, and no validated pharmacodynamic target range for circulating alpha-klotho exists in humans.
Who Is This For?
No patient is currently a candidate for klotho-raising therapy outside a registered clinical trial. Appropriate use of this page is to inform discussion with patients who ask about klotho gene therapy, klotho supplements, or consumer klotho testing. Patients with chronic kidney disease warrant particular caution: klotho biology is tightly coupled to FGF23 and phosphate handling in this population, and manipulating that axis has consequences well beyond longevity signalling.
Protocol & Dosing
Dose
Not applicable — no validated human dosing regimen exists for any alpha-klotho preparation. Commercially marketed klotho gene therapies and klotho-boosting supplement stacks use dosing derived from marketing rather than from trial data.
Frequency
Not applicable
Duration
Not applicable
Protocol Summary
There is no evidence-based klotho protocol. No recombinant alpha-klotho product is approved or available through regulated channels for any aging indication, and no dosing regimen has been validated in humans. Interventions with indirect or modest effects on circulating klotho - regular aerobic exercise, preservation of renal function, vitamin D sufficiency, and control of cardiometabolic risk - are the only measures with a defensible basis, and each is recommended on its own merits rather than as klotho therapy. Serum alpha-klotho assays are available on a research basis; there is no validated target range and no evidence that treating to a klotho level improves outcomes.
Interactions & Precautions
Contraindications
- No klotho-raising therapy should be undertaken outside a registered clinical trial
- Chronic kidney disease — klotho/FGF23/phosphate axis is disease-relevant and should not be manipulated speculatively
- Active malignancy — klotho influences Wnt, TGF-beta and IGF-1 signalling with unresolved directionality in tumour biology
- Pregnancy and breastfeeding — no safety data
Potential Risks
- •No human efficacy evidence for any klotho-raising intervention
- •Consumer klotho gene therapy is unregulated, unmonitored and has published no controlled outcome data
- •Klotho conference and press coverage frequently originates from microcap issuers with stock-promotion incentives
- •Serum klotho testing has no validated target range and is heavily confounded by kidney function
- •Unresolved directionality in cancer signalling pathways
Potential Side Effects
Practitioner Notes
Clinical annotations from Dr. Goel
Created September 20, 2026 in response to the Second Annual Klotho Conference (Miami, 18-19 Sept 2026) and the attendant patient interest. The core message for consultation: klotho has one of the most compelling preclinical records in aging biology AND no human efficacy evidence whatsoever - both halves of that sentence matter, and patients usually arrive having heard only the first. Three practical points. (1) The non-human primate cognition result (Nature Aging 2023) is real, well-conducted and worth acknowledging rather than dismissing; a single low peripheral dose improved cognition in aged rhesus monkeys with effects outlasting the protein's half-life. It is also a single-dose primate study with no human replication, and no approved product exists to deliver it. (2) When patients raise offshore klotho gene therapy, be direct: these are unregulated products with no published controlled outcome data, no safety monitoring, and immunogenicity and infusion risks that are not being characterised. Declining to recommend it is not conservatism, it is the absence of an evidence base. (3) Consumer serum klotho testing should not be ordered as a longevity biomarker - there is no validated target range, no evidence that treating to a level helps, and the measurement is dominated by renal function, which confounds every downstream association. For patients who want to act on klotho biology today, the honest answer is that aerobic exercise and preservation of renal function are the only levers with any defensible relationship to circulating klotho, and both are already recommended for other reasons. Revisit this page if a registered efficacy trial reports.
Dr. Sanjeev Goel
Chief Medical Officer, Peak Human
Cost & Access
Cost Range
Not applicable for regulated therapy. Offshore klotho gene therapy is marketed at roughly USD 15,000–25,000 with no supporting outcome data; serum klotho assays are typically USD 100–300 and are not clinically actionable.
Accessibility
Availability varies by location
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation